Back to Journals » OncoTargets and Therapy » Volume 12

RETRACTED ARTICLE: LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p

Authors Zhou K, Li S, Du G, Fan Y, Wu P, Sun H, Zhang T 

Received 11 March 2019

Accepted for publication 30 July 2019

Published 2 September 2019 Volume 2019:12 Pages 7095—7109

DOI https://doi.org/10.2147/OTT.S208329

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche



This paper has been retracted.

Zhou K, Li S, Du G, et al. Onco Targets Ther. 2019;12:7095–7109.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images in Figure 4 with those from another article. Specifically,

  • The image for Figure 4C, NC mimic, has been duplicated with the image for Figure 3D, si-NC, from Gao R, Feng Q, Tan G. microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1. Biosci Rep. 2019;39(7):BSR20182196. https://doi.org/10.1042/BSR20182196

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.